Since the outbreak of the coronavirus, the Chinese healthcare industry has made further significant progress in terms of quality and its international profile. This has made the sector more attractive to investors too, Remo Krauer, Senior Portfolio Manager at Bellevue Asset Management, writes.

Remo Krauer, Senior Portfolio Manager of Bellevue's Healthcare Asia Pacific Fund

China's economy has gone through some turbulent times since the coronavirus pandemic began more than two years ago. A rapid economic rebound after the initial shock was followed by renewed turbulence in 2021. This was triggered by the Chinese government's regulatory crackdowns on the tech, property and education industries aimed at alleviating social inequality.

Regardless of these developments, China's healthcare sector has emerged as a key industry for the country's overall economic development. Since the outbreak of the coronavirus, the Chinese healthcare industry has made further significant progress in terms of quality and its international profile. This has made the sector more attractive to investors too.

Aligned With International Standards

China's healthcare sector already underwent a regulatory transformation years ago. Clinical trials and regulatory approval pathways in China have been increasingly aligned with international standards during the past seven years.

At the same time, government procurement of generic drugs was centralized, increasing the financial muscle of government programs supporting innovative therapies. The 14th Five-Year Plan endorsed last year by the Communist Party defined innovative healthcare as a core element of its strategy for technological independence.

Demographic Change

Many facts confirm that China's healthcare industry has indeed become a key economic factor. According to recent estimates, the sector will grow by 10 percent to 12 percent on average over the next few years, which is twice as fast as China's estimated GDP growth. A key driver of this fast growth is demographic change.

In 2050, the percentage of people over 60 years old in China is projected to represent around a third of the total population. At the same time demand for high-quality healthcare services is increasing as China’s rapidly growing middle class gets richer. In order to maintain social stability, the ruling Communist Party has prioritized the nationwide expansion of an independent, high-quality system of healthcare.

Monetary and government spending policies are designed to promote this goal. Whereas the U.S. central bank is expected to announce three rate hikes this year, China is moving in the opposite direction and easing its monetary policy.

Focus on Quality Wins Out

In practical terms, the catch-up effects triggered by efforts to improve China's healthcare system mean two things. On the one hand, access to and the affordability of drugs and medical services remain important elements of government policies.

On the other hand, the improved national framework is helping China to close the gap in innovative medical treatments with the West, with the U.S. in particular. China, for example, now publishes the most scientific publications on biotechnology behind the U.S. According to a recent forecast from Bernstein Research and Evaluate Pharma, China's drug market will expand by 14 percent p.a. from 2018 to 2023 to USD 166 bn. During this same period, the share of patent-protected original medications is forecast to increase from 40 percent to 64 percent of total sales.

This number is a clear indication that China has long shifted from a focus on «growth first» to «quality first» when it comes to drug R&D quality.

The Upward Trend is Indicative

This progress goes hand in hand with the growing number of industry alliances involving Chinese companies. Chinese biotech companies are increasingly the partner of choice for drug R&D development, approval and marketing purposes for international biopharmaceutical companies seeking to enter the Chinese market.

For example, the number of active pharmaceutical ingredients from Chinese laboratories licensed out to international companies increased from 37 to 83 clinical candidates between 2018 and 2021. Meanwhile, the number of in-licensing partnerships arranged with Chinese companies rose from 3 to 21. Compared to the number of agreements announced between U.S. and European companies, these figures are still low. However, the upward trend is indicative of the general direction for the remainder of this decade.

A Growing Medical Problem in China

Looking at therapeutic areas where China is making the fastest progress with promising clinical products, four areas stand out. In oncology, Chinese biotechs have advanced novel approaches with immunotherapies, bispecific antibodies, and adjuvant antibody-drug conjugates (ADCs). They have also made progress with cell and gene therapies.

In diabetes, which is becoming a growing medical problem in China, domestic providers of diabetes treatment have been widening their share of the market. Last but not least, Chinese companies have and are developing and producing COVID-19 vaccines, antibodies and antiviral therapies. In order to meet requirements for U.S. FDA approval, companies are starting to gather data from international as well as from Chinese clinical trials.

Legend Biotech is a prime example of a Chinese biotech company on the verge of a major international breakthrough. On February 28, an FDA advisory committee will discuss and vote on the company’s CAR T-cell therapy for multiple myeloma. It has shown to be highly effective in clinical studies, so this could become the first made-in-China drug to qualify as a first-line treatment of this aggressive form of blood cancer.

What This Means For Investors

The increasing maturity of the Chinese healthcare sector has created attractive investment opportunities. Valuations are currently at low levels because the widespread sell-off in Chinese stocks in 2021 also dragged down healthcare stocks despite their generally strong fundamentals.

New-drug approvals like the announcement Legend might make next week will increasingly bring the Chinese biotech industry into the spotlight of the international investment community in the coming years. Our long-standing expertise in emerging markets enables us to quickly identify tomorrow's winners in Asian healthcare markets such as China for our funds.

An overview of Bellevue Healthcare Strategies

  • Bellevue Healthcare Strategy
  • Bellevue Sustainable Healthcare
  • Bellevue Biotech
  • Bellevue Medtech & Services
  • Bellevue Digital Health
  • Bellevue Asia Pacific Healthcare
  • Bellevue Emerging Markets Healthcare

Remo Krauer has been a Senior Portfolio Manager Healthcare Funds & Mandates at Bellevue Asset Management since 2018. Previously, he worked at Zürcher Kantonalbank, first as Senior Portfolio Manager, then as Head Portfolio Construction for Private Asset Management. He holds a Bachelors degree in Business Administration from the Zurich University of Applied Sciences.

Bellevue is a specialized asset manager listed on the SIX Swiss Exchange with core competencies covering healthcare strategies, entrepreneur strategies, alternative and traditional investment strategies. Established in 1993, Bellevue, a House of Investment Ideas staffed by 100 professionals, generates attractive investment returns and creates value-added for clients and shareholders alike. Bellevue managed assets of $14 billion as at December 31, 2021.

Disclaimer: This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to subscribe any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. Liability for the accuracy or completeness of all information in this document is expressly disclaimed. This information does not take into account the specific or future investment objectives, the financial or tax situation or the particular needs of any specific recipient This document does not constitute independent investment research. Interested investors should always seek professional advice before making an investment decision. The information in this document is provided without any guarantees or warranties, for information purposes only, and is intended only for the personal use of the recipient. Every investment involves some risk, especially with regard to of fluctuations in value and return. Investments in foreign currency involve the additional risk that a foreign currency might lose value against an investor's reference currency. This document does not reflect all possible risk factors associated with an investment in the aforementioned securities or financial instruments. Historical performance data and financial market scenarios are no guarantee or indicator of current and future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs adversely affect performance. Financial transactions should only be carried out after thorough study of the current prospectus and are only valid on the basis of/or/and are subject to the terms given in the most recently published prospectus and annual or semi-annual report. Bellevue Funds (Lux) SICAV is admitted for public distribution in Switzerland. Representative in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying Agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zurich. Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria. Paying and information agent: ERSTE BANK der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany. Paying and information agent: ACOLIN Europe GmbH, Reichenaustrasse 11a-c, D-78467 Constance. Bellevue Funds (Lux) SICAV is registered in the CNMV registry of foreign collective investment schemes distributed in Spain, under registration number 938. Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid. Prospectus, Key Investor Information Document (“KIID”), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16, CH-8700 Kusnacht. With respect to fund units distributed in or from Switzerland, the place of performance and jurisdiction is established at the registered office of the representative.